Loading
Loading
Organ & Bioregulator Research · 20mg
Janoshik-tested · 10 vials per kit
Pancragen is a synthetic tetrapeptide bioregulator studied in preclinical research for its pancreatic regulatory properties. Research has examined its potential to support pancreatic cell differentiation, improve pancreatic structure and function, promote insulin and glucagon secretion, lower fasting blood glucose, improve insulin resistance, and protect pancreatic β-cell function. Studies have also explored applications in chronic pancreatitis models.
≥98%
Purity
Lyophilised
Format
2–3 wks
Arrival
Don't want to wait 3 weeks?
Check local stock — weekday same/next-day delivery available.
Chemical Properties
Need to work out your dose?
Use our reconstitution calculator — syringe units in seconds.
Research Use Only — Disclaimer
This product is intended solely as a research chemical for laboratory and scientific study purposes only. It is not approved by the TGA or any regulatory body for human or animal consumption, therapeutic use, or clinical application. The information provided on this website is for educational purposes only. Handling must be limited to suitably qualified professionals operating within applicable laws and regulations. This product is not classified as a drug, food, cosmetic, or medicinal product and must not be used or labelled as such. By purchasing, you confirm you are a qualified research professional and accept full responsibility for compliance with all relevant laws in your jurisdiction.
Pancragen
Pancragen is a synthetic tetrapeptide developed as a pancreatic bioregulator in the Khavinson series. It is studied for regulatory effects on both exocrine and endocrine pancreatic cell populations, particularly in the context of age-related pancreatic dysfunction and insulin secretion decline.
Proposed to act via chromatin binding in pancreatic acinar cells and islet cells (beta cells, alpha cells), modulating gene expression related to insulin secretion capacity, glucagon regulation, and acinar enzyme production. Anti-apoptotic effects on beta cells under oxidative stress have been described in vitro.
Research includes pancreatic function in aged animals, diabetogenic models, and post-pancreatitis recovery. Effects on insulin secretion dynamics and beta-cell mass preservation are of interest in the context of metabolic research. As with other Khavinson peptides, clinical data is predominantly from Eastern European sources.
For research reference only. All information pertains to preclinical or published human trial data. Not intended as medical advice. This product is for research use only.
Don't have supplies? Grab them while you're here.
